Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPJOHN LICENSING CLINICAL TECHNOLOGIES' ORAL PEPTIDE DELIVERY

Executive Summary

UPJOHN LICENSING CLINICAL TECHNOLOGIES' ORAL PEPTIDE DELIVERY system for use with an unnamed pharmaceutical agent under an agreement reached May 16. Upjohn will pay Elmsford, N.Y.-based Clinical Technologies Associates $1 mil. over a one-year period, and also will purchase 87,000 shares of CTA common stock at$11.56 per share, totaling about another $1 mil. The latter part of the agreement is subject to termination before July 25, 1990 and the selection of an alternative compound for development. Clinical Technologies has roughly 4 mil. shares outstanding. Upjohn subsequently will pay Clinical Technologies an option exercise fee to obtain an exclusive license for an oral formulation of the compound. Upjohn will pay the firm an annual fee until an NDA is filed for the product and then a minimum annual royalty if marketing approval is received. Clinical Technologies also has granted Upjohn a right to first refusal for use of its technology with two other pharmaceutical agents and certain veterinary products. While neither firm would disclose compounds involved in the agreement, both Upjohn's Marogen erythropoietin product and its heparin sodium products,now marketed in injectable form, are examples of the types of drugs that could be delivered with the Clinical Technologies system. Clinical Technologies' delivery system enables the oral administration of drugs that were previously unavailable orally, including peptides such as insulin, mucopolysaccharides such as heparin, and blood growth factors ("The Pink Sheet" Feb. 19, T&G-4). The technology allows drugs to pass through the digestive system intact and enter the blood stream to be metabolized. Clinical Technologies said it has been advised that a patent on the technology is forthcoming, although formal documentation has not yet been issued. The agreement stipulates that Upjohn was to purchase first 21,750 shares of Clinical Technologies stock by May 31, with the remaining 65,250 shares to be purchased provided that the agreement is not terminated. Upjohn also has the option to buy an additional 87,000 shares at $17.34 per share. Clinical Technologies has been in operation since November 1985. Its clients include Robins, ICI Americas, American Cyanamid, Carter-Wallace, Ciba-Geigy and Genetics Institute. Late last year, American Home declined to renew its agreement with the company after an oral heparin formulation development project with subsidiary Wyeth-Ayerst did not pan out. The agreement between Clinical Technologies and Genetics Institute involves oral formulation of blood growth products. Genetics Institute's blood growth factors in development include erythropoietin, granulocyte macrophage-colony stimulating factor (GM-CSF), and M-CSF.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel